LYAR promotes the proliferation of non-small cell lung cancer and is associated with poor prognosis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The aim of the study was to investigate the clinical significance of Ly-1 antibody reactive clone (LYAR) in non-small-cell lung cancer (NSCLC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Folia Histochem Cytobiol

Title: Folia histochemica et cytobiologica

Publisher: VM Media SP. zo.o VM Group SK

ISSN (Electronic): 1897-5631

ISSN (Print): 0239-8508

Publication date (Electronic): 2021

Volume: 59

Issue: 4

Affiliations

[1 ] Department of Cardiothoracic Surgery, The Afﬁliated Suqian First People's Hospital of Nanjing Medical University, Suqian, 223800, Jiangsu, China.

[2 ] Department of Thoracic Surgery, Nantong Tumor Hospital, Nantong, 226001, Jiangsu, China.

[3 ] Department of Gastroenterology, The Afﬁliated Suqian First People's Hospital of Nanjing Medical University, Suqian, 223800, Jiangsu, China.

[4 ] Department of Thoracic Surgery, Afﬁliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.

[5 ] Department of Neurosurgery, The Afﬁliated Suqian First People's Hospital of Nanjing Medical University, Suqian, 223800, Jiangsu, China.

[6 ] Department of Cardiothoracic Surgery, The Afﬁliated Suqian First People's Hospital of Nanjing Medical University, Suqian, 223800, Jiangsu, China. sqzangqiwei@163.com.